Drug Test Detection of Cocaine for Nasal Intubation

Drug Test Detection 24 Hours After Nasal Administration of Cocaine as a Local Vasoconstrictor Prior to Nasal Intubation

The objective of this study is to determine whether it is possible to detect traces above national cut-offs of either cocaine's main metabolite benzoylecgonine in saliva or cocaine in blood 24 hours after administering 2 ml of 40 mg/ml cocaine-saline to the nasal mucosa.

The investigators hypothesize that the level of cocaine's main metabolite bezoylecgonine in saliva after cocaine administered for anesthetic purposes will be below detection limits after 24 hours.

Study Overview

• Status: Completed
• Conditions: Cocaine Adverse Reaction
• Intervention / Treatment: Drug: Cocaine Nasal

Detailed Description

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. Prior to nasal intubation the mucosa must be sufficiently lubricated and decongested in order to minimize epistaxis. When intubation is performed on awake patients anesthesia of the nose is also necessary. Cocaine has for many years been used for both decongestive and anesthetic purposes due to its unique pharmacodynamic profile. When applied to the nasal mucosa its vasoconstrictive quality aids in facilitating the inspection of the nasal cavity whilst the anesthetic effect allows for manipulation within the cavity. The vasoconstriction arises through cocaine's ability to inhibit the reuptake and metabolism of catecholamines, which then in greater concentration has adrenergic effects. By binding to and blocking axonal membrane sodium channels, cocaine interferes with the propagation of action potentials and thereby also exerts an analgesic effect.

Along with other countries Denmark has a legal zero tolerance policy for a long list of drugs in drivers including cocaine. During routine screenings or if the police suspect a driver to be under the influence of illegal drugs, they will first complete a qualitative saliva analysis testing for cocaine's main metabolite benzoyelecgonine. If the test comes out positive or there are clinical signs of drug influence, a supplementary blood sample measuring cocaine will be drawn and analyzed for use in the legal system. Repercussions from a cocaine test value exceeding the legal limit consists of a large fine, driver's license revocation and mandatory participation in a drug and alcohol course, neither of which seems fair to inflict on the uninformed and consequently unaware patient.

Pharmacokinetics for nasal cocaine have been described but no studies defining proper instructional driving precautions appear to exist. One study recommended patients be informed and consent prior to cocaine administration and be warned they may fail a drug test up to 72 hours postoperatively but as of 2021 patients are in many countries - including Denmark - still not informed about this time limit.

When administered in doses thought to avoid systemic effects, cocaine is a safe local anesthetic agent. The recommended dosage varies considerably throughout the literature with safe doses ranging between 1.5-3.0 mg/kg. The amount of cocaine absorbed has in one study been found to be 5% but has not been subsequently verified. The dosage of cocaine used prior to nasal intubation in Denmark is typically 1-2 ml of 4% cocaine resulting in a total dose of 40-80 mg. The typical 'street dose' is 40-100 mg. The Danish cut-off values for detection of cocaine's main metabolite benzoylecgonine is 200 ng/ml in saliva and 0.01 mg/kg in whole blood.

The investigators wish to evaluate whether cocaine levels exceed detection limits 24 hours after administration prior to nasal intubation.

• Study Type: Observational
• Enrollment (Actual): 27

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen, Denmark, 2100
    • Rigshospitalet, Copenhagen University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients schedualed to undergo surgery at Rigshospitalet with the use of nasal intubation.

Description

Inclusion Criteria:

• Age ≥ 18 years
• Scheduled for nasal intubation
• Proficient in spoken and written Danish
• Negative baseline cocaine saliva test

Exclusion Criteria:

• Intubation to be done on awake patient

• Pregnancy

  • Women of childbearing potential must produce a negative hCG urine stix to participate

• Known symptomatic coronary artery disease

  • As declared by patient or noted in the patient's file

• Untreated hypertension

  • As declared by patient or noted in the patient's file
  • Not taking antihypertension drugs

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Saliva analysis	Analysis of cocaine's main metabolite benzoylecgonine in saliva measured in nanograms per milliliter	24 hours after cocaine administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Whole blood toxicology	Analysis of cocaine in a whole blood sample measured in nanograms per milliliter	1 hour and 24 hours after cocaine administration

Collaborators and Investigators

• Sponsor: Rigshospitalet, Denmark
• Investigators: Principal Investigator: Mo Haslund Larsen, MD, Rigshospitalet, Denmark

Study record dates

Study Major Dates

• Study Start (Actual): March 22, 2023
• Primary Completion (Actual): May 27, 2023
• Study Completion (Actual): May 27, 2023

Study Registration Dates

• First Submitted: April 12, 2022
• First Submitted That Met QC Criteria: April 12, 2022
• First Posted (Actual): April 19, 2022

Study Record Updates

• Last Update Posted (Actual): June 1, 2023
• Last Update Submitted That Met QC Criteria: May 31, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Dopamine Agents; Anesthetics, Local; Dopamine Uptake Inhibitors; Vasoconstrictor Agents; Cocaine
• Other Study ID Numbers: 50510617; 2021-000709-26 (EudraCT Number); H-21028055 (Other Identifier: Regional Committee on Health Research Ethics)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No